Get the Stockscreener App
0.00
100.00%
-0.06
Nkgen Biotech Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$0.06
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
$3,000
Net Income/Loss:
$-23.55M
P/E Ratio:
0.00
EPS:
-1.2183
Net Cash Flow:
$-19.75M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-92.59%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.345
Nkgen Biotech Inc Stock (NKGN) Company Profile
Compare NKGN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKGN
Nkgen Biotech Inc
|
0.00 | 0 | 3,000 | -23.55M | -19.75M | -1.2183 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.17 | 117.08B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
772.03 | 82.63B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
742.79 | 45.82B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.38 | 42.92B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
305.39 | 33.54B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nkgen Biotech Inc Stock (NKGN) Latest News
NKGen Biotech Secures Additional Debt Financing from AlpineBrook - TipRanks
Nkgen Biotech amends loan agreement to secure additional $343,000 funding - Investing.com
NKGen Biotech Adds $343,000 via Fourth Amendment to AlpineBrook Secured Note; Principal Now $27.1M - TradingView
NKGen Biotech (NKGN) adds $343,000 under AlpineBrook note - Stock Titan
NKGen Biotech, Inc. and NKGen Operating Biotech, Inc. Enter Amendment to Secured Promissory Note Increases Loan Principal and Funding - marketscreener.com
NKGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NKGNNKGen Biotech Inc Latest Stock News & Market Updates - Stock Titan
NKGen Biotech increases loan principal by $251,000 under amended agreement By Investing.com - Investing.com Nigeria
NKGen Biotech increases loan principal by $251,000 under amended agreement - Investing.com South Africa
NKGen Biotech expands debt financing with loan amendment - TipRanks
NKGen Biotech Signs Amendment to Secured Promissory Note With AlpineBrook Capital - TradingView
Pre-Market Top Gainer: NKGNW NKGen Warrants NASDAQ $0.0301 Feb 2026: key setup - Meyka
Head to Head Comparison: NKGen Biotech (NYSE:NKGN) versus SQZ Biotechnologies (NYSE:SQZ) - Defense World
NKGen Biotech amends loan agreement and extends forward purchase deal By Investing.com - Investing.com Nigeria
NKGen Biotech amends loan agreement and extends forward purchase deal - Investing.com
NKGen Biotech Secures Additional Funding via Note Amendment - TipRanks
NKGen Biotech Signs Multiple Financing Agreements - TradingView
NKGen Biotech confirms successful acquisition of NKMax - intellectia.ai
NKGen Biotech Appoints Bruce Miller to Scientific Advisory Board - Intellectia AI
NKGen Biotech appoints neurology expert Dr. Bruce Miller to advisory board - Investing.com Nigeria
NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board - The Globe and Mail
NKGen Biotech, Inc. SEC 10-Q Report - TradingView — Track All Markets
Nkgen Biotech amends loan agreement to secure additional $295,000 funding - Investing.com India
Nkgen Biotech amends loan agreement to secure additional $295,000 funding By Investing.com - Investing.com South Africa
NKGen Biotech Expands Debt Financing Through Note Amendment - TipRanks
NKGen Biotech Signs Amendment to Secured Promissory Note With AlpineBrook Capital GP I - TradingView — Track All Markets
NKGen Biotech, Inc. and NKGen Operating Biotech, Inc., Enter into an Amendment to Certain Secured Promissory Note with AlpineBrook Capital GP I Limited - marketscreener.com
NKGen Biotech enters $25.8 million secured note agreement with AlpineBrook Capital - Investing.com Australia
NKGen Biotech enters $25.8 million secured note agreement with AlpineBrook Capital By Investing.com - Investing.com South Africa
NKGen Biotech Secures New Promissory Note Financing - TipRanks
NKGen Biotech Signs Secured Promissory Note With AlpineBrook Capital GP I - TradingView
NKGen Biotech issues statement on NKGen Korea board appointments - MSN
Financial Review: Alpha Cognition (OTC:ACOGF) vs. NKGen Biotech (NYSE:NKGN) - Defense World
Analyzing Genocea Biosciences (NASDAQ:GNCA) and NKGen Biotech (NYSE:NKGN) - Defense World
NKGen Biotech, Inc. Issues Statement on Recent Board - GlobeNewswire
Is NKGen Biotech, Inc. technically bullish or bearish? - Markets Mojo
NKGen Biotech announces new funding to regain compliance with reporting obligations and listing standards - MSN
NKMAX CO., Ltd. has Changed its Name to NKGen Korea - marketscreener.com
Sorrento Therapeutics (NASDAQ:SRNE) versus NKGen Biotech (NYSE:NKGN) Head-To-Head Review - Defense World
Sorrento Therapeutics (OTCMKTS:SRNEQ) & NKGen Biotech (NYSE:NKGN) Head-To-Head Review - Defense World
Reviewing NKGen Biotech (NYSE:NKGN) and Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World
Total debt per share of NKGen Biotech Inc. – OTC:NKGN - TradingView
Revenue per share of NKGen Biotech Inc. – OTC:NKGN - TradingView
NKGen Biotech, Inc. (NKGN) Eps Diluted (Quarterly) - Zacks Investment Research
Nkgen Biotech’s Promising Alzheimer’s Study: A Potential Game-Changer? - TipRanks
Nkgen Biotech Inc Stock (NKGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.28%
17.88%
Cap:
|
Volume (24h):